Treponemal glycoconjugate inhibits Toll‐like receptor ligand‐induced cell activation by blocking LPS‐binding protein and CD14 functions

Y. Asai,M. Hashimoto,T. Ogawa
DOI: https://doi.org/10.1002/eji.200324219
2003-11-01
European Journal of Immunology
Abstract:Spirochetes are well‐known as causative agents of various chronic infectious diseases. Glycolipids of small‐sized Treponema spirochetes have been shown to exhibit immunostimulating activities. In this study, we found that a glycoconjugate preparation obtained from Treponema medium (Tm‐Gp), an intermediate‐sized oral Treponema seen in subgingival plaque from patients with chronic periodontal diseases, diminished the LPS‐induced activation of a human monocytic cell line, while TNF‐α‐induced activation was unaffected. NF‐κB activation in Ba/F3 cells expressing murine Toll‐like receptor (TLR) 4 and MD‐2 was inhibited by Tm‐Gp in a CD14/LPS‐binding protein (LBP)‐dependent manner when stimulated with LPS or its active center lipid A but not whenstimulated with Taxol. Tm‐Gp blocked the binding of LPS to immobilized CD14 and LBP and inhibited nitric oxide (NO) production by a murine Mϕ cell line following stimulation with peptidoglycan and LPS in the presence of FBS, while NO production in response poly (I:C) RNA or CpG DNA remained unaffected. The inhibitory effects of Tm‐Gp seem to be attributable to the lipophilic portion of the glycoconjugate. These results indicate that T. medium contains a glycoconjugate possessing an inhibitory effect on TLR‐mediated cell activation through interaction with LBP and CD14.
What problem does this paper attempt to address?